Clinical Trial Update: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase II randomized trial evaluating eribulin mesylate with or without pembrolizumab in metastatic hormone receptor-positive breast cancer completed with posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-05-11